Injectable isoxazoline pharmaceutical compositions and their use against parasitic infestations - Patents.com
Isoxazoline compounds with controlled particle sizes in veterinary compositions address the issue of injection site irritation, offering effective and long-lasting parasitic control with minimal adverse reactions.
Patent Information
- Application Number
- JP2023070584
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-12-21
- Filing Date
- 2023-04-24
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2038-11-06
AI Technical Summary
Existing injectable isoxazoline compositions for treating parasitic infestations cause significant injection site irritation, which is a common issue in veterinary applications.
Development of isoxazoline compounds with defined particle sizes ranging from about 25 microns to about 250 microns, administered with pharmaceutically acceptable excipients, to minimize injection site irritation while maintaining effective parasitic control.
The compositions provide broad-spectrum efficacy against ectoparasites like fleas and ticks with minimal injection site irritation, ensuring a desirable safety profile and prolonged efficacy.
Smart Images

Figure 0007578752000029 
Figure 0007578752000030 
Figure 0007578752000031
Abstract
Description
[Background technology]
[0001] Isoxazoline compounds are known in the art, and these compounds and antiparasitic Their use as biological agents is described, for example, in U.S. Patent Application US2007 / 0066617, and International Patent Applications WO2005 / 085216, WO2007 / 079162, WO 2009 / 002809, WO2009 / 024541, WO2009 / 003075, This is described in WO2010 / 070068 and WO2010 / 079077. The disclosures of these references, as well as those cited herein, are incorporated by reference. This class of compounds is effective against ectoparasites, i.e. parasitic insects such as fleas and ticks, and It is known to have excellent activity against insects and mites.
[0002] An example of an isoxazoline compound is carbamoylbenzamidophenyl isoxazoline. (CBPI) compounds. Specific examples of CBPI compounds include 4-[5-(3,5-dichlorophenyl) phenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl] -2-Methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]- Benzamide (CAS RN[864731-61-3])-USAN Fluralaner do. [ka]
[0003] The CBPI compound fluralaner is disclosed in patent application WO2005 / 085216. There are.
[0004] WO2015 / 048371 discloses a spirocyclic isoxazoline compound, a biopolymerizable compound, and at least one carrier, solvent or excipient. A composition is disclosed.
[0005] WO2016 / 138339 describes a compound comprising at least one isoxazoline active agent, a poloxamer, A long-acting injectable formulation is disclosed that includes a summer and a co-solvent. There is no disclosure of the formulation being a suspension or the particle size of the isoxazoline.
[0006] WO2016 / 164487 describes a method for treating parasitic organisms comprising administering to said organism at least one inhibitor. Sustained release injection comprising a soxazoline active agent, a pharma- ceutically acceptable polymer and a solvent The present application discloses an injectable veterinary pharmaceutical formulation. There is no disclosure.
[0007] U.S. Patent No. 9,609,869 is for use in agriculture, horticulture, livestock and companion animals. -Based on isoxazoline derivatives for use in controlling related pests - Patents.com No injectable formulation or administration to animals is disclosed.
[0008] U.S. Patent Application Publication No. 2017 / 0239218 discloses a method for producing a compound comprising the steps of: Contains active agents, liquid PEG and / or neutral oils, long-lasting to eliminate parasites The present invention discloses an injectable composition that is an active ingredient in a suspension formulation and particles of isoxazoline. No diameter is disclosed.
[0009] Both of these references have demonstrated long-term efficacy against parasites and reduced injection site irritation. Solution to the problem of identifying injectable isoxazoline compositions with reduced risk The means are not disclosed. [Prior art documents] [Patent documents]
[0010] [Patent Document 1] US2007 / 0066617 [Patent Document 2] WO2005 / 085216 [Patent Document 3] WO2007 / 079162 [Patent Document 4] WO2009 / 002809 [Patent Document 5] WO2009 / 024541 [Patent Document 6] WO2009 / 003075 [Patent Document 7] WO2010 / 070068 [Patent Document 8] WO2010 / 079077 [Patent Document 9] WO2015 / 048371 [Patent Document 10] WO2016 / 138339 [Patent Document 11] WO2016 / 164487 [Patent Document 12] U.S. Patent No. 9,609,869 [Patent Document 13] US Patent Application Publication No. 2017 / 0239218 Summary of the Invention [Problem to be solved by the invention]
[0011] Thus, the present invention provides a method for treating parasitic infections with long-term efficacy and low risk of injection site irritation. Reduced injectable isoxazoline compositions are provided. [Means for solving the problem]
[0012] One embodiment of the present invention is a compound of formula (I) [ka]
[0013] is an isoxazoline compound of the formula R 1 is halogen, CF3, OCF3 or CN; n is an integer from 0 to 3 inclusive, preferably 1, 2 or 3: m is 1 or 2; R 2 is C1-C3 haloalkyl, CF3 or CF2Cl, T is a 5- or 6-membered ring or bicycle, optionally substituted with one or more groups Y. Ku; Y is methyl, halomethyl, halogen, CN, NO2, NH2-C=S, or two adjacent groups Y together form a chain; Q is X-NR 3 R 4 , N.R. 5 -NR 6 -XR 3 , XR 3 or 5-membered N-heteroa an aryl ring, optionally substituted with one or more groups; X is CH2, CH(CH3), CH(CN), CO, CS; R 3 is hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, oxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl ethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethy haloethylaminocarbonylethyl, tetrahydrofuryl, Methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, proton Cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl haloethylaminocarbonylcyclopropyl, alkylsulfani alkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, cycloalkyl kill, [ka] TIFF0007578752000004.tif80143
[0014] and; Where: Z A is hydrogen, halogen, cyano or halomethyl (CF3); R 4 is hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, Toxomethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, Aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, di Methoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl methylaminocarbonylmethyl or haloethylaminocarbonylethyl. the law of nature; R 5 is H, alkyl or haloalkyl; R 6 is H, alkyl or haloalkyl; Or, where R 3 and R 4 Together, [ka]
[0015] A compound forming a substituent selected from the group consisting of a salt or N-oxide thereof An injectable pharmaceutical composition comprising particles and a pharma- ceutically acceptable excipient, The isoxazoline compound is measured by a static light scattering device using a volume weighted particle size distribution has a D50 of about 25 microns to about 250 microns.
[0016] Additional embodiments include administering to an animal in need thereof an effective amount of the injectable pharmaceutical composition described above. A method for treating or preventing a parasitic infestation in an animal comprising: [Brief description of the drawings]
[0017] [Figure 1] 1 is a graph showing mean fluralaner plasma concentrations following subcutaneous administration of a fluralaner large particle suspension in dogs. [Diagram 2] Mean fluralaner plasma concentrations to demonstrate the effect of irradiation and in the absence of poloxamer. [Diagram 3] 13 is a graph showing the mean fluralaner plasma concentrations of injectable formulations with different particle size distributions. [Figure 4] Mean fluralaner plasma concentrations to determine the effect of varying NaCMC and poloxamer concentrations, as well as different D50 particle sizes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Injectable compositions of the present invention include particles of an isoxazoline compound having a defined particle size. The composition exhibits desirable bioavailability and duration of efficacy while providing minimal toxicity at the injection site. The composition was also found to cause only mild irritation in warm-blooded animals and birds. In addition, the compositions provide a desirable safety profile for the recipient. A single dose is generally administered to treat one or more parasites (e.g. ectoparasites, e.g. fleas, ticks, etc. It provides potent activity against mites and mites while providing rapid onset of activity and long-lasting activity. They also tend to offer longer duration and / or a more favorable safety profile. It was done.
[0019] The present invention also provides an antiparasitic effective amount of at least one isoxazoline compound of a defined particle size. Administering an effective amount of an injectable composition containing a phosphorus compound together with a pharma- ceutically acceptable excipient. The present invention provides a method for treating or preventing parasitic infection and infestation in animals, comprising: Surprisingly, the isoxazoline-containing compositions of the invention described herein Other injectable compositions containing isoxazoline active agents known in the art are also disclosed. Harmful parasites compared to adults (e.g. ectoparasites such as fleas and ticks) It provides superior, broad-spectrum efficacy more rapidly and for longer duration than It was found to cause minimal irritation at the injection site.
[0020] The pharmaceutical compositions of the present invention can be administered by subcutaneous or intramuscular injection. Intravenous injection is also possible.
[0021] definition Isoxazoline compounds are known in the art and this class of compounds is useful for treating parasitic It is known to have excellent activity against infestations of animals, such as ticks and fleas. Various embodiments of the isoxazoline compounds of the present invention are provided below.
[0022] Injection site irritation is the reaction that occurs at the injection site and in the surrounding tissues when an animal receives an injection of a pharmaceutical composition. Such damage can be swelling, skin discoloration and tissue necrosis. Some injection site irritation is inevitable in some animals, but should not persist for longer than 2-3 days. Injection site swelling larger than 2 x 2 cm lasting for a short period of time is not tolerated by veterinarians and animal owners. Minimal injection site irritation should last for less than 2 to 3 days. This criterion is defined as an injection site irritation smaller than 2 x 2 cm. It is generally accepted by veterinarians and their clients in the context of animals receiving standard injections.
[0023] As used herein, the particle size data reported are based on conventional methods well known to those skilled in the art. Various particle techniques, such as static light scattering (also known as laser diffraction), image analysis or sieving The particle size is a volume weighted value as determined by particle sorting. A discussion is provided below.
[0024] Pharmaceutically acceptable excipients are inert substances that form a vehicle or medium for a drug. It is.
[0025] An "infestation" of a parasite is one in which the parasite is present in sufficient numbers to pose a risk to humans or animals. This presence may occur in the environment, for example in animal bedding, or on the skin or The infestation may be on the hair, etc. The infestation referred to may be internal to the animal, e.g. in the blood or elsewhere. When the term parasitism is in the internal tissue of the organism, the term is also intended to be synonymous with the term "infection" as commonly understood in the art. .
[0026] A suspension is a mixture of particles with a fluid (liquid or gas) or a solid. It refers to the state of a substance when it is not dissolved in water.
[0027] A diluent is a substance used to dilute a mixture, suspension, or solution.
[0028] A vehicle is a solvent (or diluent) in which a pharma- ceutical active agent is formulated or administered. It is a carrier or inert medium used as a solvent (solvent).
[0029] The pharmaceutical compositions of the present invention are useful for the treatment of ectoparasites, i.e., humans and livestock and companion animals. harmful to animals or capable of spreading disease or acting as a vector of disease in them They are particularly valuable in arthropod control.
[0030] Important arthropod parasites - ectoparasites (insect and acarid pests) are listed below. It will be described in more detail.
[0031] Biting insects include, for example, Hypoderma sp. ), Gastrophilus in horses and The migratory dipterans, such as Cuterebra sp., erous) larvae, as well as all types of biting fly and mosquito species, e.g. An example of a sexually active adult fly is the horn fly, Haematobia japonica. Haematobia irritans, horse fly y) Tabanus spp., stable fly Stomoxys calcitrans, Black fly, Simulium spp., deer fly (deer fly) Chrysops spp., lice E (louse fly) or Melophagus ovinus inus), tsetse fly, i.e. Glos Parasitic fly maggots include, for example, the bot fly. fly) (Oestrus ovis and Oestrus spp.) Cuterebra spp.), blow fly, or Phoenicia Phaenicia spp., screwworm fly Cochliomyia hominivorax , cattle grub, Hypoderma sp. p.), and fleeceworms. Mosquitoes include, for example, Culex spp., Anopheles spp. and Aedes spp.
[0032] As for mites, chicken mites, Delmanis moths, Dermanyssus gallinae; itch mites e or scab mite) or mange mite (subspecies of Astigmata) Order Astigmata, e.g. Sarcoptidae sp. p.), e.g. Sarcoptes scabiei; Mange mites, e.g. Chorioptes bovis s bovis, Psoroptes ovis and Demodectes Demodex canis and other species of the family Pso roptidae spp.; ear mite Otodectes sinensis Chis (Otodectes cynotis); chigger, e.g. Trombiculidae spp., e.g., North American trombiculid North American chigger, Trombicula Alfreduge Includes Trombicula alfreddugesi.
[0033] Ticks include, for example, Argasidae spp. Soft-bodied ticks, such as Arga s spp. and Ornithodoros spp.; Ixodidae Hard-bodied ticks including Ixodidae spp. ck), e.g. Ixodes ricinus, Ixodes Ixodes scapularis, Rhipicephalus sanguineus Rhipicephalus sanguineus, Haema physalis spp., Dermacentor reticulatus reticulatus, Dermacentor variabilis variabilis), Amblyomma americanum ricanum and Boophilus spp.
[0034] Lice include, for example, blood-sucking lice, such as Menopon species. spp.) and Bovicola spp.; biting lice, e.g. Haematopinus spp., Linognathus spp. (Linognathus spp.) and Solenopotes spp. s spp.)
[0035] Fleas include, for example, Ctenocephalides spp. For example, the dog flea (Ctenocephalides canis) phalides canis) and the cat flea (Ctenocepha Ctenocephalides felis, etc.; Rat fleas Xenopsylla spp., e.g. orienta l rat flea)(Xenopsylla cheopis) as well as Pulex spp., e.g. the human flea man flea) (Pulex irritans) .
[0036] As bedbugs, for example, there are the family Cimicidae, i.e. The common bed bug (Cimex rectularius) ectularius), also known as the kissing bug The species of the Triatomid subfamily, which includes the triatomid bugs atominae spp.); e.g. Rhodnius prolixus prolixus and Triatoma spp.
[0037] The compositions of the present invention are effective in preventing eggs, nymphs and larvae, nymphs and It is valuable for the treatment and control of various life cycle stages of parasites, including adult stages. do.
[0038] For the avoidance of doubt, as used herein, "treatment" means " includes references to curative and palliative treatments, and "control of ectoparasites." The reference is to killing, repelling or eliminating pests on the animal and in the animal's environment. and incapacitating, preventing, eliminating, mitigating, minimizing, It includes eradicating.
[0039] "Ectoparasite infestation control" refers to the reduction of the number of parasites in and / or on an animal. reducing or diminishing the incidence of parasitic infestations in or on animals; It means to inhibit development in whole or in part.
[0040] Prevention is the stopping of a new or subsequent infestation or infection from becoming established.
[0041] Control or the "efficacy" of a compound is measured by the reduction in parasite counts after the first dose ranging from 5% to approximately 100% reduction means that the amount of arthropods (e.g. insects, mites) is reduced. The effect of the compounds of the invention may be, for example, insecticidal and / or acaricidal. Ovigenic, larvicidal, nymphicidal and The effect may be direct or / and adulticidal. i.e. the parasite is killed immediately or after some time has elapsed, e.g. when molting occurs. This may be by killing or destroying their eggs when they are infected, or indirectly This may manifest as, for example, a reduction in egg production and / or hatchability.
[0042] For in vivo administration of the compounds according to the invention, an effective amount is synonymous with a "pharmaceutical effective amount." This may be due to symptoms and / or infestation of parasites by treated animals. treat or ameliorate symptoms or the control of parasites in and / or on animals reducing the number and / or overall development of parasitic infestations in or on animals; This latter amount is a dose or amount that can be determined by one of skill in the art, e.g. For example, by observing or detecting changes in clinical symptoms or behavior of treated animals, and It is also easily possible to observe or detect the relative change in the number of parasites after such treatment. It is decided.
[0043] Systemic administration of a drug means that it reaches its target (organ or parasite) through the bloodstream. .
[0044] By animal is meant mammals, including companion animals. means a dog, cat or horse.
[0045] A reconstitutable formulation is one in which the vehicle is in one container and the active ingredient is in another container; The formulation is one in which the two containers are combined at the same time prior to administration.
[0046] The vehicle contains additives necessary for the formulation, such as diluents, wetting agents, antifoaming agents, pH adjusters, etc. Contains some or all of them.
[0047] In certain embodiments, the isoxazoline compounds for use in the present invention are The present invention also includes its physiologically acceptable salts, esters and / or N-oxides. A reference to a isoxazoline compound refers equally to any of its polymorphic forms or stereoisomers. It extends to.
[0048] In one embodiment, the pharmaceutical composition according to the present invention is A racemic mixture of oxazolines may be used, which is similar to the enamel of the isoxazoline compounds described above. Alternatively, the pharmaceutical composition may contain isothiocyanates, isothiocyanates, or isothiocyanates as defined herein. One of the enantiomers of Sazoline is stereoisomerically enriched compared to the racemic mixture. The pharmaceutical composition may contain an isoxazoline compound. Essentially pure stereoisomers of the phosphorus compounds may be used. Enriched or purified isoxazoline stereoisomer preparations are known in the art. Examples include catalytic asymmetric synthesis or separation of diastereomeric salts. (e.g., WO2009 / 063910 and J (See P2011 / 051977).
[0049] In certain embodiments of the isoxazolines for use in the present invention, T is [ka] TIFF0007578752000007.tif206148TIFF0007578752000008.tif72145
[0050] wherein in T-1, T-3 and T-4, the group Y is selected from hydrogen, halogen, It is methyl, halomethyl, ethyl or haloethyl.
[0051] In certain embodiments of the isoxazoline for use in the present invention, Q is [ka]
[0052] where R 3 , R 4 , X and Z A is as defined above, Then, Z B teeth, [ka]
[0053] and Z D teeth, [ka]
[0054] It is.
[0055] In one embodiment, the isoxazoline for use in the present invention is selected from the group consisting of those shown in Table 1. As stated above.
[0056] Table 1: [Table 1] TIFF0007578752000013.tif115153
[0057] Table 1 (continued): [Table 2] TIFF0007578752000015.tif21152
[0058] In one embodiment, the isoxazoline for use in the present invention is selected from the group consisting of those listed in Table 2. As stated above.
[0059] Table 2: [Table 3] TIFF0007578752000017.tif123155
[0060] In one embodiment, the isoxazoline for use in the present invention is the compound: [ka]
[0061] where R 1a , R 1b , R 1c are, independently of each other: hydrogen, Cl or CF3 It is.
[0062] Preferably, R 1a and R 1c is Cl or CF3, and R 1b is hydrogen And T is [ka]
[0063] where Y is methyl, bromine, Cl, F, CN or C(S)NH2; is 1 or 2; and Q is as defined above.
[0064] In certain embodiments of the isoxazoline defined herein, R 3 is H, R 4 is:-CH2-C(O)-NH-CH2-CF3, -CH2-C(O)-NH-CH 2-CH3, -CH2-CH2-CF3 or -CH2-CF3.
[0065] In one embodiment of the pharmaceutical composition according to the invention, the isoxazoline is fluralaner , afoxolaner, lotilaner, or sarolaner. do.
[0066] In one embodiment, the compound of formula (I) is 4-[5-(3,5-dichlorophenyl -5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2- Methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benz Amide (CAS RN 864731-61-3-USAN Fluralaner).
[0067] In another embodiment, the compound of formula (I) is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydrazine -5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[ (2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (CAS RN 1093861-60-9, USAN-afoxolaner).
[0068] In one embodiment of the pharmaceutical composition according to the present invention, the isoxazoline is lotilaner ( CAS RN:1369852-71-0;3-Methyl-N-[2-oxo-2-(2, 2,2-trifluoroethylamino)ethyl]-5-[(5S)-5-(3,4,5-trifluoroethylamino)ethyl]- (trichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazole-3- thiophene-2-yl-thiophene-2-carboxamide).
[0069] In one embodiment of the pharmaceutical composition according to the present invention, the isoxazoline is sarolaner ( CAS RN: 1398609-39-6; 1-(5′-((5S)-5-(3,5-di Chloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroiso Oxazol-3-yl)-3′-H-spiro(azetidine-3,1′-(2)benzofuran 2-(methylsulfonyl)ethanone.
[0070] In another embodiment, the compound of formula (I) is (Z)-4-[5-(3,5-dichloro phenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl] -N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928 789-76-8).
[0071] In another embodiment, the compound of formula (I) is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H- [Isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CAS RN 1164267-94-0).
[0072] In another embodiment, the compound of formula (I) is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydrazine -5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[ (2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (CAS RN 1093861-60-9, USAN-afoxolaner).
[0073] In another embodiment, the compound of formula (I) is 5-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoro methyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2, 2-Trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide (CAS RN 1231754-09-8).
[0074] The long-acting injectable compositions of the present invention include a pharma- ceutically acceptable excipient. Pharmaceutically acceptable additives include, but are not limited to, surfactants, antioxidants, , preservatives, pH stabilizers (e.g., buffers), and other inactive additives. In an embodiment, the compositions of the present invention comprise from about 0.01% to about 20% (w / v) of a pharmaceutical In other embodiments, the composition may contain from about 0.01% to about 5% (w / v), about 0.1% to about 10% (w / v), or about 0.1% to about 5% (w In another embodiment, the composition may comprise about 5 to about 15% (w / v), or about 5 to about 10% (w / v) of a pharma- ceutically acceptable additive. In yet another embodiment, the composition may comprise about 7 to about 10% of a pharma- ceutically acceptable The composition may include additives that are added to the composition.
[0075] The surfactant may be present in the composition of the present invention in an amount of from about 0.1% to about 10% (w / w), from about 1% to about 10% (w / w), or from about 5% to about 10% (w / w). Typically, the surfactant is present in an amount of from about 0.1% to about 5% (w / w), or from about 1 to about 5% (w / w). Examples of surfactants that may be used in the composition include, but are not limited to, However, it is not a glyceryl monooleate, polyoxyethylene sorbitan fatty acid ester. sorbitan esters, including sorbitan monooleate (Span® 20) Polysorbate 20 and Polysorbate 80 are included. Polysorbate, da-tocopherol polyethylene glycol 1000 succinate Polypropylene glycol (TPGS), sodium lauryl sulfate, ethylene oxide and propylene oxide Copolymers (e.g., poloxamers, such as LUTROL® F87, etc.); Polyoxyl 35 Castor Oil (Cremophor® EL), Polyoxyl 4 0 Hydrogenated Castor Oil (Cremophor® RH40), Polyoxyl 60 Polyethylene including hydrogenated castor oil (Cremophor® RH60) propylene glycol castor oil derivatives; propylene glycol monolaurate (LAUROGLY) COL®; Glycerol Caprylate / Caprate (CAPMUL® (MCM), polyglycolized glycerides (GELUCIRE®, PE G300 Caprylic / Capric Glycerides (Softigen® 767) , PEG 400 Caprylic / Capric Glycerides (Labrasol®), PEG300 oleic acid glyceride (Labrafil® M-1944CS ), PEG 300 linoleic acid glyceride (Labrafil® M-2125 Glyceride esters including polyoxyl 8 stearate (PEG 400 monostearate); stearate), polyoxyl 40 stearate (PEG1750 monostearate, etc. ) including polyethylene glycol stearates and polyethylene glycol hydrochlorides Polyethylene glycol stearate (synonyms include macro Gol stearate, polyoxyl stearate, polyoxyethylene stearate, ethylene Contains toxyl stearates; CAS No. 9004-99-3, 9005-08- 7) is a monostearate and distearate of mixed polyoxyethylene polymers. It is a mixture of phosphate esters. Polyethylene glycol hydroxystearate is Mixtures of monoesters and diesters of hydroxystearic acid with polyethylene glycol One polyethylene glycol hydroxystearyl alcohol that may be used in the composition is In another embodiment, the stearate is polyethylene glycol 12-hydroxystearate. In the composition of the present invention, the surfactant polyethylene glycol 15-12-hydroxy Roxystearate (Kolliphor® HS15 from BASF), 1 Monoester and diene ester of 2-hydroxystearic acid with 15 moles of ethylene oxide Again, these compounds and their amounts may vary depending on the subject. In another embodiment of the present invention, the composition of the present invention comprises a surfactant. Examples of suitable oleic acid derivatives include polyoxyl 35 castor oil (Kolliphor® EL). In another embodiment, the composition of the present invention comprises polyoxyl 40 hydrogen as a surfactant. Added castor oil (Kolliphor® RH40) or polyoxyl 60 water The compositions of the present invention may also include a combination of surfactants. obtain.
[0076] The compositions of the present invention may contain other inactive ingredients such as antioxidants, preservatives or pH stabilizers. These compounds are well known in the art of composition. Antioxidants, e.g., biphenyls, Vitamin E, Alpha Tocopherol, Ascorbic Acid, Ascorbyl Palmitate, Kue Acid, Fumaric Acid, Malic Acid, Sodium Ascorbate, Sodium Metabisulfate , sodium metabisulfite, n-propyl gallate, BHA (butylated hydroxypropyl ester Anisole), BHT (butylated hydroxytoluene), BHA and citric acid, monothiophene Oglycerol, tert-butylhydroquinone (TBHQ), benzyl alcohol, etc. Antioxidants may be added to the compositions of the present invention. Antioxidants are generally present in the compositions of the present invention at least in part. From about 0.01% to about 3%, or from about 0.01 to about 2% ( In another embodiment, the composition is present in an amount of about 0.05 to about 1.0 % (w / w) of antioxidants.
[0077] Preservatives, such as benzyl alcohol, may be present in the composition in amounts ranging from about 0.01 to about 10.0%. with about 0.05 to about 5.0% being particularly preferred. , paraben (methylparaben and / or propylparaben), benzalkonium chloride , benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butylparaben , cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, Ethylparaben, imidourea, methylparaben, phenol, phenoxyethanol, Phenylethyl alcohol, phenylmercury acetate, phenylmercury borate, phenyl water Silver nitrate, potassium sorbate, sodium benzoate, sodium propionate phosphate, sorbic acid, thimerosal, etc. The preferred range for these compounds is about 0. 01 to approximately 5%.
[0078] Compounds that stabilize the pH of the composition may also be present. Again, such compounds may be present in the composition. The methods of using these compounds are well known to practitioners in the art. , e.g., acetic acid / acetate, malic acid / malate, citric acid / citrate, tartaric acid / tartrate acid salt, lactic acid / lactate, phosphoric acid / phosphate, glycine / glycimate ), Tris, glutamic acid / glutamate, and sodium carbonate. These include systems that are suitable for use as sedatives, particularly sodium phosphate or sodium citrate.
[0079] Oil suspensions (non-aqueous suspensions) are prepared by dissolving the isoxazoline compound in a vegetable oil, such as peanut oil. , olive oil, sesame oil or coconut oil, or a mineral oil, for example liquid paraffin, or The drug may be formulated by suspending it in other pharma- ceutically acceptable oils. Oil suspensions are A thickening agent, such as beeswax, hard paraffin or cetyl alcohol, may be included. The composition may be preserved by the addition of an antioxidant, such as ascorbic acid, or other known preservatives. It is possible.
[0080] In yet another embodiment of the present invention, the injectable composition of the present invention which is an oil suspension comprises Non-limiting examples of these co-solvents include benzoic acid, Medium chain like benzyl, ethyl acetate, triacetin, lipids, C8-C10 triglycerides Triglycerides, including triglycerides, such as capric / caprylic triglyceride Propylene glycol derivatives (e.g. propylene glycol monolaurate) , Caprylocaproyl polyoxyl-8 glyceride (Labrasol) (non-ionic water-dispersible surfactant, isopropyl myristate, or at least one of these cosolvents It contains a mixture of at least two.
[0081] In another embodiment, the injectable compositions of the present invention, which are non-aqueous, contain a neutral solvent as a co-solvent. Neutral oils may include triglycerides of fractionated vegetable fatty acids with chain lengths of C8 to C10. Two commercially available products are MIGLYOL® 810 and MI It is known as GLYOL® 812. In another embodiment, the neutral oil is Fractionated plant extracts with chain lengths of C8 to C10 combined with linoleic acid (approximately 4-5%) It is a triglyceride of fatty acids. The commercially available product is MIGLYOL® 818 In yet another embodiment, the neutral oil is combined with succinic acid. It is a glycerol ester of fractionated vegetable fatty acids with chain lengths of C8 and C10. The commercially available product is known as MIGLYOL® 829. Neutral oils are made up of propylene glycol of saturated vegetable fatty acids with chain lengths of C8 and C10. A commercially available product is MIGLYOL® 840 (propylene glycol). In yet another embodiment, In the present case, the co-solvent can be a mixture of two or more neutral oils.
[0082] The aqueous suspension may be prepared by mixing the isoxazoline compound with an additive suitable for the preparation of an aqueous suspension. Such additives may include suspending agents, such as carboxymethylcellulose. Sodium cellulose, methylcellulose, hydroxypropyl methylcellulose, alginate Sodium phosphate, polvinylpyrrolidone, Gum lagocanthus and gum acacia; wetting and dispersing agents, such as phosphatides of natural origin, e.g. lecithin, or condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearates, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g., heptane Tadecaethyleneoxycetanol, or ethylene oxide with fatty acids and hexitols Condensation products with partial esters derived from, for example, polyoxyethylene sorbitol monooleate esters, or partial esters derived from ethylene oxide and fatty acids and hexitol anhydrides The aqueous suspension also includes condensates thereof with polyethylene sorbitan monooleate. , one or more preservatives, e.g., ethyl benzoate, or n-propyl benzoate, p-hydroxybenzoate, benzoic acid, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents and / or Bittering agents such as those described above may be included.
[0083] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water include isoxazolidinium phosphate. The compound may be mixed with a wetting and dispersing agent, a suspending agent and one or more preservatives. Wetting dispersing agents and suspending agents are exemplified by those already mentioned above.
[0084] In one embodiment, the isoxazoline compound is an aqueous solution in which the liquid phase (diluent) is water. It is suspended in a suspension.
[0085] In another embodiment, the liquid phase (diluent) of the aqueous suspension comprises water and a co-solvent.
[0086] Co-solvents that may be used in the injectable compositions of the invention that contain an isoxazoline compound include: It may be a single co-solvent or a blend of co-solvents.
[0087] In one embodiment, the co-solvents used in the injectable compositions of the invention are aqueous. includes polar solvents that are miscible in water. Non-limiting examples of these co-solvents include: Ethanol, isopropanol, benzyl alcohol, glycol ethers (e.g. but limited to diethylene glycol monoethyl ether DGME, Transcutol®, butyl diglycol, dipropylene glycol Ethylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene Glycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, etc. Liquid polyethylene glycol (PEG) (e.g. PEG400), propylene Glycols, carbonates (e.g., propylene carbonate), 2-pyrrolidone, N -Methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethy glycerol formal or The solvent may be a mixture of at least two of these solvents.
[0088] In one embodiment, the compositions of the present invention comprise a polar protic solvent and Examples include, but are not limited to, alcohols, such as ethanol and isopropanol. or a glycol or glycol ether. The long-acting injectable compositions of the present invention are prepared by dissolving in polar aprotic solvents, such as N-methylpyrrolidone. dimethyl isosorbide, dimethylacetamide, dimethyl sulfoxide or propane Contains propylene carbonate.
[0089] In certain embodiments, the isoxazoline compounds may exist in various isomeric forms. A reference to an isoxazoline compound always includes all possible isomeric forms of such a compound. Unless otherwise stated, compound structures in which no particular conformation is shown are intended to represent the structure of the compound. Compositions of all possible conformers, as well as compositions of less than all possible conformers In some embodiments, the compound is chiral. In some embodiments, the compound is a non-chiral compound.
[0090] In certain embodiments, the isoxazoline compounds of formula (I) are described, for example, in patent application US 2007 / 0066617, WO2007 / 079162, WO2009 / 002809 , WO2009 / 080250, WO2010 / 070068, WO2010 / 0790 77, 2011 / 075591 and WO2011 / 124998. or according to any of the methods described herein, which are within the capabilities of a person skilled in the art who is an expert in chemical synthesis. The product of the present invention can be prepared according to any other process. For this purpose, the skilled artisan should refer, inter alia, to "Chemical Abstracts" and the references cited therein. The entire content of the material provided is deemed to be freely available for use.
[0091] In certain embodiments, the isoxazoline compound is suspended in the composition. In an embodiment, the suspension is aqueous. In an alternative embodiment, the suspension is non-aqueous. do.
[0092] In certain embodiments, the pharmaceutical composition is substantially free of organic solvents.
[0093] In one embodiment, the pharmaceutical composition comprises a surfactant / wetting agent. In this case, the surfactant / wetting agent is a poloxamer. Alternatives to poloxamers are other water-soluble / Water-miscible nonionic surfactants include sorbitan fatty acid esters (S pan), polyoxyethylene sorbitan fatty acid ester (polysorbate / Tween ), polyoxyethylene castor oil derivative (Cremaphor), polyoxyethylene Thearates, lecithin and TPGS (d-α-tocopheryl polyethylene glycol 1 000 succinate). The surfactant / wetting agent is present in the composition at about 0.01% w / v to about 0.5% w / v, or from about 0.05% w / v to about 0.1% w / v .
[0094] Poloxamers are made up of a central polyoxypropylene (poly(propylene oxide)) hydrophobic The structure is a hydrophilic chain of polyoxyethylene (poly(ethylene oxide)) adjacent to two hydrophilic chains. It is a non-ionic triblock copolymer made of (See ).
[0095] Poloxamer 124 is a poly(ethylene glycol)-block-poly(propylene glycol) copolymer. Recall)-block-poly(ethylene glycol), CAS No. 9003-11-6 Yes Also known as Lutrol L44 or Kollisolv P124.
[0096] Lutrol F68 is another poly(ethylene glycol)-block-poly(propylene glycol) Poly(ethylene glycol)-block-poly(ethylene glycol), poloxamer 188 Also known as Kolliphor P188.
[0097] Lecithin is a component of phosphatidylcholine, phosphatidylethanolamine, and phosphatidyl It is a mixed glycerophospholipid containing inositol and phosphatidic acid.
[0098] In certain embodiments, the pharmaceutical composition comprises a suspending agent. The binder is sodium carboxymethylcellulose (NaCMC). In this case, the suspending agent is methylcellulose or polyvinylpyrrolidone.
[0099] In certain embodiments, the pharmaceutical composition comprises an antifoaming agent. Simethicone is an α-(trimethylsilyl)-ω-methylpoly[oxy] It is a mixture of silane (dimethylsilylene) and silicon dioxide.
[0100] In certain embodiments, the pharmaceutical composition comprises a preservative. is benzyl alcohol. In an alternative embodiment, the preservative is m-cresol, salt benzalkonium chloride, methylparaben or propylparaben.
[0101] Injectable pharmaceutical compositions are prepared by mixing the solid components together and then dissolving the solid mixture in a diluent. It may be prepared by suspending.
[0102] The method for preparing an injectable pharmaceutical composition includes mixing isoxazoline particles with a wetting agent and a diluent. This includes combining with
[0103] In certain embodiments, the pharmaceutical composition is a reconstitutable solid, which can be diluted prior to injection. It is reconstituted with
[0104] In certain embodiments, the diluent is water. In alternative embodiments, the diluent is isopropyl alcohol. An oil or solvent in which the oxazoline compound has little or no solubility.
[0105] The pharmaceutical composition further comprises a surfactant / wetting agent. Specific surfactants / wetting agents and Alternatives to surfactants / wetting agents are discussed herein and in the examples.
[0106] The pharmaceutical composition may further comprise additional additives such as a suspending agent, an antifoaming agent, or a preservative. Specific examples of suitable additives and alternative agents are discussed herein and in the Examples below.
[0107] Particle size and measurement of isoxazoline compounds Injectable compositions of the present invention include particles of an isoxazoline compound having a defined particle size. The composition has been found to have particularly beneficial properties.
[0108] In certain embodiments, the isoxazoline compound is measured by a static light scattering device. Particle size distribution D50 is about 25 microns to about 250 microns, and particle size is about 11 microns to Approximately 250 microns, particle size from approximately 50 microns to approximately 150 microns, particle size from approximately 75 microns from about 130 microns, particle size from about 90 microns to about 110 microns, and about 30 microns The particle size ranges from about 100 microns.
[0109] Particle size distribution describes the relative amount of particles present according to size. D10 is the average particle size of D50 is the particle size distribution that represents the size below which 50% of particles are smaller. D90 is the particle size distribution that represents the size below which 90% of particles are smaller. This is a particle size measurement distribution that represents the size below which the particle size distribution is smaller than the particle size distribution.
[0110] In certain embodiments, the particle size D10 is about 10 μm, about 20 μm, about 30 μm, It is about 40 μm, about 50 μm, about 60 μm or about 80 μm.
[0111] In certain embodiments, the particle size D50 is about 50 μm, about 75 μm, about 80 μm, Approximately 90μm, approximately 100μm, approximately 110μm, approximately 120μm, approximately 130μm, approximately 140μm Or about 150 μm.
[0112] In certain embodiments, the particle size D90 is about 100 μm, about 130 μm, about 150 μm, or about 200 μm. μm, about 175 μm, about 200 μm or about 250 μm.
[0113] In certain embodiments, the particle size D10 is about 20 to 35 μm and the particle size D5 The particle size D90 is about 90 to 105 μm, and the particle size D90 is about 155 to 175 μm. be.
[0114] In certain embodiments, the particle size D10 is about 25 to 30 μm and the particle size D5 The particle size D90 is about 160 to 170 μm. be.
[0115] In certain embodiments, the particle size D10 is about 10 to 20 μm and the particle size D5 The particle size D90 is about 170 to 185 μm. be.
[0116] In certain embodiments, the particle size D10 is about 10 to 15 μm and the particle size D5 The particle size D90 is about 175 to 180 μm. be.
[0117] In certain embodiments, the particle size D10 is about 10 to 25 μm and the particle size D5 0 is about 40 to 60 μm, and the particle size D90 is about 95 to 100 μm. .
[0118] In certain embodiments, the particle size D10 is about 15 to 20 μm and the particle size D5 The particle size D90 is about 45 to 55 μm, and the particle size D90 is about 90 to 95 μm.
[0119] In certain embodiments, the particle size D10 is about 30 to 50 μm, and the particles The diameter D50 is approximately 70 to 130 μm.
[0120] In certain embodiments, the particle size D10 is about 35 to 45 μm, and the particles The diameter D50 is approximately 90 to 110 μm.
[0121] In a particular embodiment, the particle size D10 is about 40 μm and the particle size D5 0 is approximately 100 μm.
[0122] Volume weighted particle size was determined by sieving, microscopy or laser diffraction (Malvern or Sympatec). Volume weighted particle size measurement is performed using the H Malvern Mastersizer 20 with ydro 2000G measuring cell 00 or using a Horiba LA-910 laser scattering particle size distribution analyzer. Volume weighted particle size can be measured using a Sympatec Helos instrument. It can be measured by:
[0123] For use in the present invention, the isoxazoline compound is preferably present in a pharmaceutical composition according to the present invention. is present in an amount between about 0.1 and about 50% w / v of the final pharmaceutical composition according to the invention. The oxazoline may comprise between about 10 and about 45% w / v of the pharmaceutical composition according to the invention; Between about 45% w / v; between about 15 and 35% w / v, or between about 25% w / v and about 35% w / v between about 1% w / v and about 12% w / v, or between about 3% w / v and about 9% w / v. % w / v.
[0124] In one embodiment, the amount of isoxazoline compound in the pharmaceutical composition according to the present invention is In one embodiment, the pharmaceutical composition according to the present invention is about 30% w / v. The amount of the isoxazoline compound in the pharmaceutical composition is about 7.5% w / w of the pharmaceutical composition according to the present invention. / v.
[0125] In one embodiment, the pharmaceutical composition is a ready to use composition. This means that the composition is ready for injection. In the pharmaceutical composition, the pharmaceutical composition must be reconstituted prior to injection. is reconstituted in water prior to injection.
[0126] In certain embodiments, the pharmaceutical composition is administered in combination with an additional therapeutic agent. The administration of the therapeutic agents may be in the same composition or in separate compositions. , a parasiticide or a vaccine.
[0127] In another embodiment, the additional therapeutic agent is another parasiticide. In one embodiment, the macrocyclic lactone is moxidectin or milbemycin.
[0128] Other active ingredients include isoxazoline compounds, avermectins (e.g. ivermectin , Selamectin, Doramectin, Abamectin and Eprinomectin); Milbemycin pro-benzimidazoles (e.g., benzimidazole derivatives, e.g. febantel, netobimin and thiophanate; For example, thiazole benzimidazole derivatives (e.g. thiabendazole and cyanbendazole) azoles), carbamate benzimidazole derivatives (e.g. fenbendazole, arbutinazole, Bendazole (oxide), mebendazole, oxfendazole, parbendazole , oxibendazole, flubendazole and triclabendazole); imidazo Thiazoles (e.g. levamisole and tetramisole); tetrahydropyrimidines (e.g. morantel and pyrantel), salicylanilides (e.g. closantel, oxyclosantel, zanid, rafoxanide and niclosamide); nitrophenol compounds (e.g. nitro oxynil and nitroscanate; benzene disulfonate amides (e.g., clorsulon); pyrazinoisoquinolines (e.g., praziquantel and and epsiprantel); heterocyclic compounds (e.g. piperazine, diethylcarbamazine and and phenothiazines); dichlorophene, arsenicals (e.g. thiacetamide, melorxamide, melorsamine and arsenamide; cyclooctadepsipeptides (e.g. emodepside); paraherquamide (e.g. delcantel); and amine No-acetonitrile compounds (e.g., monepantel, AAD1566); amidine compounds (e.g., amidantel and tribendimidine), all of which are pharma- ceutical acceptable. forms such as salts, solvates or N-oxides.
[0129] In one embodiment, moxidectin is present at about 0.1% w / v to about 1.0% w / v. It exists in amounts between
[0130] One embodiment of the present invention is to administer to an animal in need thereof an effective amount of the injectable pharmaceutical composition described above. The present invention relates to a method for treating or preventing a parasitic infestation in an animal, the method comprising administering to an animal a compound comprising the steps of:
[0131] In certain embodiments, the animals suffer from minimal injection site irritation. injection site irritation of less than 2 x 2 cm lasting less than 2 to 3 days It means.
[0132] In some embodiments, the animal is a companion animal.
[0133] In certain embodiments, the companion animal is a dog or a cat.
[0134] The optimum amount to be used for best results will, of course, depend on the particular ingredient being used. Soxazoline compounds, species of animals to be treated, route and formulation of administration, and parasites In general, good results are obtained by administering to the subject a compound of formula (I) according to the present invention. The isoxazoline compounds were administered at doses of about 0.01 to 200 mg / kg animal body weight. In one embodiment, the amount is from 0.1 to 100 mg / kg of animal body weight, or from 0.1 to 100 mg / kg of animal body weight. Dosed at 0.5 to 50 mg per kg of body weight or 1 to 30 mg per kg of animal body weight When administered intravenously, such total dose may be given in single or divided doses.
[0135] The method of the present invention relates to the presence of arthropod parasites, such as those listed above. It will be appreciated by those skilled in the art that these compounds are useful in treating diseases and disorders known to cause It is understood that such diseases (parasitic diseases) are, for example, severe parasitic infestations, such as from ticks. The presence of numerous mammary glands at sites where pressures on the host are such that they can have large-scale pathogenic consequences in animals. It is caused by infestation of dogs by mites.
[0136] As used herein, the term "administer" or "administration" refers to administration within or to an animal. For the purpose of controlling parasitic infestations on plants, the compounds of formula (I), their salts and solvates are also or a prodrug thereof, or a compound of formula (I), a salt, solvate or prodrug thereof "Delivery of a pharmaceutical composition containing the compound to an animal" refers to the delivery of the compound to an animal.
[0137] Administration of the compounds of the invention can be intermittent and can be daily, weekly, biweekly, monthly, bimonthly, etc. The treatment may be administered once a week, once a quarter, once a half year, once a year, or less frequently. For example, the parasite(s) to be treated, the level of infestation, the type of animal, mammal or bird, and The nature of the substance depends on factors such as the type and the environment in which it exists.
[0138] Injectable pharmaceutical compositions may be administered daily, weekly, monthly, semi-annually or yearly. The injectable pharmaceutical composition may be administered monthly, every two months, every three months, every four months, every five months, or every six months. Every 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, It may be administered every 14 months, 15 months, 16 months, 17 months or 18 months.
[0139] In certain embodiments, the injectable isoxazoline pharmaceutical composition is administered in a separate injectable In some embodiments, the administration is simultaneous or sequential. It is.
[0140] In one embodiment of the injectable pharmaceutical composition, the particle size D50 of the isoxazoline compound is About 75 microns to about 130 microns, and the particle size D10 is about 30 microns. to about 50 microns.
[0141] One embodiment of the invention is a kit for treating or preventing a parasitic infestation in an animal. So, this kit is Contains two or more containers, a) Solid crystalline isoxazoline compounds; b) A vehicle containing a pharma- ceutically acceptable excipient capable of forming a suspension with the compound of a). Kuru; and c) Indication for combining the solid crystalline isoxazoline compound with the vehicle prior to injection. Includes instructions.
[0142] Here, for the solid crystalline isoxazoline compound, the particle size D50 is about 75 microns. The particle size D10 is about 30 microns to about 50 microns. It's Kron.
[0143] In another embodiment, the isoxazoline compound is fluralaner.
[0144] Another embodiment is a method for the prevention and treatment of parasites in an animal comprising administering the above kit to an animal in need thereof. A method for treating or preventing parasitic infestation.
[0145] In additional embodiments, the injectable pharmaceutical composition is reconstituted with a vehicle.
[0146] In additional embodiments, the vehicle includes a diluent, and may include a wetting agent, a defoamer, a pH adjuster, The composition may also include a dispersing agent and / or a suspending agent. EXAMPLES
[0147] Example 1 - Ready-to-use injectable Fluralaner suspension Table 3 [Table 4] TIFF0007578752000021.tif224168TIFF0007578752000022.tif86167
[0148] The following procedure was used to make the formulation of Example 1A.
[0149] 1. Add approximately 80% of the total amount of water for injection.
[0150] 2. Add suspending agent (sodium carboxymethylcellulose (NaCMC)) and mix until smooth. The mixture was mixed with a one-head mixer for approximately 5 minutes.
[0151] 3. The mixture was further mixed with a homogenizer until no lumps remained.
[0152] 4. Add the wetting agent (Poloxamer 124) and mix with an overhead mixer until uniform. It came together.
[0153] 5. Add the preservative (benzyl alcohol (BA)) and mix homogenously with an overhead mixer. Mix until combined.
[0154] 6. Sodium phosphate was added and mixed with an overhead mixer until uniform.
[0155] 7. Fluralaner was added and mixed with a homogenizer until no lumps remained.
[0156] 8. Gently mix the antifoaming agent (Simethicone) with an overhead mixer until uniform. (5 minutes).
[0157] 9. The pH of the mixture was adjusted to pH 7.0-7.4 by adding HCl. Mix gently with a hand mixer for 5 minutes until uniform.
[0158] 10. Add water to the final mass for injection and then mix in an overhead mixer. Mix gently until homogenous (5 min).
[0159] 11. The resulting formulation was placed into injection vials and sealed with stoppers.
[0160] 12. The vials were autoclaved at 121°C for 15 minutes.
[0161] A similar procedure was used to prepare the formulations of Examples 1AA, 1B-1J and the placebo. The batch sizes ranged from 50 mL to 1000 mL. Fluralaner Crystalline (API) Volume weighted particle size was measured by static light scattering (laser diffraction) (Sympatec Helos) The particle size distribution was determined by measuring the particle size distribution.
[0162] Example 2 - Evaluation of injection site reactions The administration site was examined on the day of treatment before treatment, 30 minutes after administration, 1 day after administration, and then 2 days after administration for up to 3 weeks after administration. If a dog exhibited an administration site reaction at any evaluation time, the study supervisor scheduled an additional evaluation. A fixed time point could be determined. Dogs showed administration site reactions at the last scheduled evaluation time point. Once this was determined, additional assessments on each individual dog were performed at 2-3 day intervals until the reaction had resolved.
[0163] The administration area was initially observed for swelling, erythema or other signs. Regardless of the severity of the injury, the area was palpated for swelling, pain, and elevated temperature. The system used was: Erythema, warmth and pain: 0 = no response, 1 = slight reaction; 2 = moderate response; 3=severe reaction.
[0164] ·swelling: Dimensions (measured with a graduated device): Length x Width x Height Hardness: Hard / Soft Movable: Yes / No Connections with surrounding tissues: Separate / diffuse.
[0165] Other observations at the administration site (e.g., scabbing, wounds, scratches) should be recorded in descriptive terms. Ta.
[0166] Each study group consisted of 6 to 10 dogs. The placebo group did not receive any fluralaner. Data below show the number of dogs with injection site irritation and the size of the irritation in cm. , and represents the duration of the stimulus.
[0167] Table 4 Injection site stimulation [Table 5]
[0168] These data suggest that injection site irritation with the smaller fluralaner particle size formulation is related to particle size. Specifically, the effect of fluralaner was approximately 5 μg / kg. The micronized formulation 1AA caused significant swelling at the injection site lasting for 12 to 14 days. Irritation occurred, but only lasted for a short period with the larger particle formulation 1J (particle size 100 μm). The results were similar to those of the placebo group, with only slight swelling and no significant changes in the blood flow. was.
[0169] Example 3 - Pharmacokinetic Study Survey A: Fluralaner 5 micron 7.5% suspension (Example 1AA) and Fluralaner A 7.5% suspension of 40 microns of flannel (Example 1D) was administered to eight beagle dogs at 15 ml each. The test substances were administered subcutaneously in a single dose of 1000 mg / kg body weight (BW). Local tolerance of the test substances was evaluated at intervals up to 28 days after administration. Blood samples for determination of fluralaner plasma concentrations were taken before and after treatment. 2 hours and 8 hours, as well as 1, 2, 3, 5, 7, 10, 14, 21, 28, 35, At 42, 49, 56, 70, 84, 98, 112, 126, 140 and 154 days Collected.
[0170] Survey B:A 100 micron 7.5% suspension of Fluralaner (Example 1J) was administered to three A single dose of 10 mg / kg BW was administered subcutaneously to dog. Local tolerance of the test substance was evaluated 28 days after administration. Blood samples for determination of fluralaner plasma concentrations were collected before and after treatment at intervals up to 12 h. , as well as 1, 3, 5, 7, 10, 14, 21, 28, 35, 49, 56, and 63 days after treatment. and at 70 days.
[0171] During the first few days, the initial absorption of all formulations was comparable, which suggests a similar onset of efficacy. The 100 micron suspension at 10 mg / kg BW is safe for the target animals. At the same time, plasma concentrations are still sufficient. The 40 micron suspension is sufficiently high to suggest efficacy against the microparticles administered at the same dose. Compared with the fertilized suspension, it showed higher plasma concentrations at 84 days and longer-lasting efficacy against ticks. This is expected to provide sustained
[0172] Overall, larger particles are more effective at preventing infection while presenting a lower risk of adverse events such as injection site irritation. It provides sufficient levels of fluralaner in the blood to provide long-lasting efficacy against ticks.
[0173] Example 4 - Efficacy Testing Example 4A Using Rhipicephalus sanguineus and Amblyomma americanum on dogs A dose characterization study was performed to define effective doses: 10, 15, and 20 mg fluralane. These studies evaluated doses of fluralane per kg body weight. Each group consisted of 10 dogs per treatment group, each containing 8 to 10 dogs. On the day after treatment, each dog was infested with 50 ticks of each species. Live ticks were counted on all dogs 72 hours after the first dose and the % efficacy versus untreated controls was evaluated. Efficacy was determined by calculating the percent reduction in live ticks or live ticks. The results from one of them are presented in Tables 5 and 6. [Table 6] [Table 7]
[0174] In the examples, Amblyomma americanum and Rhipicephalus sanguineus Efficacy against ticks was tested because these parasite species are dose limiting. are known to be effective against these ticks (i.e., the doses effective against these ticks are not known to be effective against other tick species). and from today, its efficacy against fleas (>90% mortality) The rate was at least 1.2% in Amblyomma americanum and Rhipicephalus sanguineus. As long as activity against This is because it can be expected that this can be achieved by administration of
[0175] Thus, the composition according to the present invention comprises at least Amblyomma americanum and Li For a period of at least 90 days, i.e., companion animals of Picephalus sanguineus The composition is effective for controlling flea infestations in animals, particularly dogs and cats.
[0176] Example 4B Results from additional dose characterization studies are summarized. These studies showed that Three doses (10, 15 and 20 mg / kg) were evaluated. A turbid formulation was prepared as shown in Example 1J above. The efficacy against S. sanguineus ticks was tested (see Table 7). A second study evaluating efficacy against fleas at approximately 6 months was tested in dogs (see Table 8). (I want to be). [Table 8] [Table 9]
[0177] Results from these studies showed that injectable The efficacy of fluralaner in suspension against R. sanguineus was demonstrated.
[0178] The efficacy of the 15 and 20 mg / kg doses was also demonstrated against A. americanum for 6 months after injection. This was proven.
[0179] All three doses were 100% effective in reducing live fleas on dogs 6 months after treatment It has been demonstrated that fleas are more susceptible to fluralaner than ticks. Because of the formulation, flea efficacy is expected to last for 12 months. This is true for the abundance-limiting species R. sanguineus and A. americanum.
[0180] Example 5 - Reconstitutable injectable fluralaner formulation Additional examples of injectable Fluralaner suspension formulations were prepared as reconstitutable formulations. Formulation 5A was made using the procedure described above.
[0181] A. Vehicle 1. Add approximately 80% of the total amount of water for injection.
[0182] 2. Add suspending agent (sodium carboxymethylcellulose (NaCMC)) and mix until smooth. The mixture was mixed with a one-head mixer for approximately 5 minutes.
[0183] 3. The mixture was further mixed with a homogenizer until no lumps remained.
[0184] 4. Add the wetting agent (Poloxamer 124) and mix with an overhead mixer until uniform. It came together.
[0185] 5. Add the preservative (benzyl alcohol (BA)) and mix homogenously with an overhead mixer. Mix until combined.
[0186] 6. Sodium phosphate was added and mixed with an overhead mixer until uniform.
[0187] 7. Gently mix the antifoaming agent (Simethicone) with an overhead mixer until uniform. (5 minutes).
[0188] 8. The pH of the mixture was adjusted to pH 7.0-7.4 by adding HCl. Mix gently with a hand mixer for 5 minutes until uniform.
[0189] 9. Add water to the final mass for injection and then mix evenly with an overhead mixer. Mix gently until uniform (5 min).
[0190] 10. The resulting formulation was placed into injection vials and sealed with stoppers.
[0191] 11. The vials were autoclaved at 121°C for 15 minutes.
[0192] B. Active ingredients 1. Solid Fluralaner was added to a vial and sealed. 2. The vials were terminally sterilized by gamma irradiation.
[0193] C. Formation of a reconstituted injectable formulation 1. Add the vehicle from vial A to the active ingredient vial from B and shake. 2. The resulting suspension was ready for injection.
[0194] A similar procedure was used to prepare the formulations of Examples 5B-H. Batch sizes ranged from 50 mL to The range was 1000 mL.
[0195] The volume-weighted particle size of crystalline Fluralaner (API) was measured by static light scattering (laser diffraction) (S The particle size distribution was determined by measurement using a ympatec Helos.
[0196] The compositions of Formulations 5A-H are given in Table 9.
[0197] Table 9 [Table 10]
[0198] Example 6 - Pharmacokinetic Study of Reconstitutable Injectable Fluralaner Formulations The pharmacokinetic properties of the formulation of Example 5 were evaluated as described in Example 3, except as noted below. It was carried out as follows.
[0199] Example 6A: Formulation 5B (Fluralaner, D50 = 100 microns, 15% suspension, 5B (irradiated) and The 5D (irradiated, no poloxamer) and 5D (irradiated, no poloxamer) samples were then administered to 16 and 16 beagle dogs, respectively. The test substance was administered subcutaneously in a single dose of 20 mg / kg BW at 100 rpm for 21 days at intervals. Blood samples for determination of fluralaner plasma concentrations were taken before and after treatment. 8 hours, as well as 1, 3, 5, 7, 10, 14, 21, 28, 35, 42, 49, 56 , at 70, 84, 98, 112, 126, 140, 154, 168 and 182 days Collected.
[0200] Please refer to Figure 2.
[0201] Example 6B: Formulation 5A (Fluralaner 100 microns (D10=20, D50=100) 15% suspension Turbidity), 5B (Fluralanel 100 microns (D10=40, D50=100) 15% Suspension), and 5C (Fluralaner 130 microns (D10=50, D50=130) 15% suspension) was administered subcutaneously to 10 beagle dogs at a single dose of 20 mg / kg BW. Local tolerance of the test article was assessed at intervals up to 21 days after administration. Blood samples for determination of plasma concentration were collected before treatment, 8 hours after treatment, and at 1, 3, 5, 7 , 10, 14, 21, 28, 35, 42, 49, 56, 70, 84, 98, 112, 12 Harvested at 6, 140, 154, 168 and 182 days.
[0202] Please refer to Figure 3.
[0203] Example 6C: Formulation 5B (Fluralaner 100 micron 15% suspension), 5E (Fluralaner 100 15% suspension, containing 2.3% NaCMC), 5F (Fluralaner 100 μm Klon 15% suspension, containing 0.05% poloxamer), 5G (Fluralaner 77 micrograms) Samples of 5H (15% suspension of 5H) and 5H (116 micron suspension of 5H) were A single dose of 20 mg / kg BW was administered subcutaneously to 10 beagle dogs. Blood samples for determination of fluralaner plasma concentrations were collected at intervals up to 21 days after dosing. Before treatment, 8 hours after treatment, and at 1, 3, 5, 7, 10, 14, 21, 28, 3 5, 42, 49, 56, 70, 84, 98, 112, 126, 140, 154, 168 The samples were collected at time points 182 and 183.
[0204] Please refer to Figure 4.
[0205] Example 7 - Evaluation of injection site reactions of reconstitutable formulations Evaluation of the formulation of Example 5 was carried out as described in Example 2.
[0206] These formulations were evaluated in the pharmacokinetic studies described in Example 6. There were no significant injection reactions during evaluation of the formulation.
Claims
1. An injectable pharmaceutical composition comprising particles of an isoxazoline compound, fluralaner, and a pharma- ceutically acceptable excipient, wherein the isoxazoline compound has a volume weighted particle size distribution D50 of 50 microns to 150 microns and a particle size D10 of 35 microns to 45 microns, as measured by a static light scattering device; and pharma- ceutically acceptable excipients include sodium carboxymethylcellulose, poloxamer, benzyl alcohol, simethicone, and sodium phosphate. The pharmaceutical composition.
2. 2. The injectable pharmaceutical composition of claim 1, wherein the isoxazoline compound is in suspension in the composition.
3. 3. The injectable pharmaceutical composition of any of claims 1 to 2, having a particle size distribution D50 of 75 microns to 150 microns.
4. 4. The injectable pharmaceutical composition of any of claims 1 to 3, having a particle size distribution D50 of 90 microns to 110 microns.
5. 5. The injectable pharmaceutical composition of any of claims 1 to 4, wherein the isoxazoline compound is present in an amount between 5% w / v and 50% w / v.
6. 6. The injectable pharmaceutical composition of claim 5, wherein the isoxazoline compound is present in an amount between 25% w / v and 35% w / v.
7. 7. The injectable pharmaceutical composition of claim 6, wherein the isoxazoline compound is present in an amount between 5% w / v and 10% w / v.
8. The injectable pharmaceutical composition of any of claims 1 to 7, wherein the composition is reconstituted with a vehicle.
9. The injectable pharmaceutical composition of any of claims 1 to 8, wherein the composition further comprises another anti-parasitic compound.
10. 10. The injectable pharmaceutical composition of claim 9, wherein the parasiticidal compound is a macrocyclic lactone.
11. 11. The injectable pharmaceutical composition of claim 10, wherein the macrocyclic lactone compound is selected from moxidectin and milbemycin.
12. 12. The injectable pharmaceutical composition of claim 11, wherein the parasiticidal compound is moxidectin.
13. 13. The injectable pharmaceutical composition of claim 12, wherein moxidectin is present in an amount between 0.1% w / v and 1.0% w / v.
14. A method for treating or preventing a parasitic infestation in a non-human animal comprising administering to said non-human animal in need thereof an effective amount of the injectable pharmaceutical composition of any of claims 1-13.
15. The method of claim 14, wherein the non-human animal suffers from minimal injection site irritation.
16. The method of any of claims 14 to 15, wherein the non-human animal is a companion animal.
17. 17. The method of claim 16, wherein the companion animal is a dog.
18. The method of any one of claims 14 to 17, wherein the injectable isoxazoline pharmaceutical composition is administered together with a separate injectable parasiticidal composition.
19. 20. The method of claim 18, wherein the administration is simultaneous or sequential.
Citation Information
Patent Citations
Injectable formulation containing asenapine and method of treatment using the same
JP2012530759A
Crystalline form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide
JP2013528177A
Long acting injectable formulations containing isoxazoline active agents, methods and uses thereof
JP2018509405A
Isoxazoline-substituted benzamide compound and pesticide
US20070066617A1
Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
US20170239218A1
